London, February 20, 2026, 08:37 GMT — Regular session
GSK plc shares edged up 0.4% to 2,234 pence in early London trade on Friday, after closing at 2,226 a day earlier. The stock traded in a narrow range of 2,232 to 2,243 pence.
The move is small, but it lands on a morning of housekeeping items that can still tug at big defensives: capital returns, boardroom disclosures, and a sudden need to cut reputational exposure.
GSK said it had no plans to work with Global Counsel further, as the consultancy prepared to enter administration after client departures linked to disclosures around co-founder Peter Mandelson’s past ties to Jeffrey Epstein, Reuters reported.
In a separate filing, GSK said it bought back 410,000 ordinary shares on Feb. 18 through broker BNP Paribas at prices between 2,244 and 2,281 pence, with a volume-weighted average price of 2,268.77 pence. The shares will be held in treasury, and the company said it has repurchased 830,000 shares since Feb. 17.
Another disclosure showed Chief Scientific Officer Tony Wood will receive a cash payment of £204,048.58, before tax withholding, linked to the vesting of an award tied to 8,996.851 notional shares, according to the notice.
Buybacks reduce the number of shares available to trade over time, which can lift earnings per share, though the impact depends on the price paid and what profits do next. Treasury shares typically do not carry voting rights and do not receive dividends.
The Global Counsel item is not about drugs or sales, but investors have seen enough of these reputational flare-ups to know they can widen fast. Big clients tend to move first and explain later.
But the share support from repurchases can also fade if markets start pricing in tougher conditions for pharma earnings, or if investors decide a defensive bid has run too far.
The next clear calendar marker is the dividend timetable: GSK’s quarterly dividend went ex-dividend on Feb. 19, with a record date of Feb. 20 and payment due on April 9, according to the company’s published schedule.
Related articles: LSE:GSK
